RIGL News and Press, Rigel Pharmaceuticals Inc. From 11/04/25

2025-11-04 20:07:15 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout Rige...

2025-11-04 20:06:29 ET Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript

2025-11-04 16:24:30 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout Seeking Alpha’s Quant Rating on Rigel Pharmaceuticals Historical ...

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update PR Newswire Third quarter 2025 total revenue of approximately $69.5 million , including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million  ...

Advanced Energy Industries Inc. (AEIS) is expected to report $1.16 for Q3 2025 Neuropace Inc. (NPCE) is expected to report $-0.2 for Q3 2025 Oportun Financial Corporation (OPRT) is expected to report $0.2 for Q3 2025 trivago N.V. (TRVG) is expected to report $0.07 for Q3 2025 Alle...

2025-11-03 17:35:55 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout Rigel targets up to $280M 2025 revenue as IRA boosts sales and pipeline advances...

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition PR Newswire Oral presentation to feature updated data from the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients...

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third...

2025-10-26 09:45:35 ET On Wednesday, Avadel Pharmaceuticals ( AVDL ) accepted a buyout off from Alkermes plc ( ALKS ) after settling litigation with Jazz Pharmaceuticals ( JAZZ ) . It should be noted this just the latest of several notable acquisi...

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS PR Newswire Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS ...